This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
Orthopedics Device Space Gaining Prominence: 3 Stocks in Focus
by Riya Anand
Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.
Medtronic (MDT) Boosts Surgical Robotics Wing With New Deal
by Zacks Equity Research
According to Medtronic (MDT), Touch Surgery Enterprise is the first AI-powered platform of its kind for the operating room (OR). It is compatible with Medtronic's Hugo robotic-assisted surgery (RAS) system.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
4 Stocks in Spotlight With AI Making Inroads in MedTech
by Riya Anand
MedTech stocks like Medtronic (MDT), Stryker (SYK), Allscripts Healthcare Solutions (MDRX) and Syneos Health (SYNH) are evolving rapidly in the field of AI-driven technologies.
Top Research Reports for Intel, Lockheed Martin & IBM
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Lockheed Martin (LMT) and IBM (IBM).
BAX vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BAX vs. SYK: Which Stock Is the Better Value Option?
Vocera (VCRA) Beats Q4 Earnings Estimates on Top-Line Growth
by Zacks Equity Research
Higher revenues, software strength, and broad-based growth ably supported by dynamic business fundamentals enable Vocera (VCRA) to beat fourth-quarter 2021 earnings estimates.
Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.
Stryker (SYK) Q4 Earnings Lag Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of -0.37% and 1.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Earnings Preview: Stryker (SYK) Q4 Earnings Expected to Decline
by Zacks Equity Research
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stryker (SYK) to Boost Digital Capabilities With New Buyout
by Zacks Equity Research
Stryker (SYK) inks a deal with Vocera to enhance its digital healthcare offerings.
Vocera (VCRA) to be Acquired by Stryker for $79.25 Per Share
by Zacks Equity Research
The Vocera (VCRA) acquisition will help Stryker accelerate its digital goals to improve the lives of caregivers and patients.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
Company News for Dec 28, 2021
by Zacks Equity Research
Companies in The News Are: GDDY,BBIO,UAL,MBOTSYK
Top Stock Reports for Alibaba, Lowe's & American Express
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Lowe's Companies, Inc. (LOW), and American Express Company (AXP).
AHCO vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. SYK: Which Stock Is the Better Value Option?
Stryker (SYK) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Despite pandemic-led disruptions, Stryker's (SYK) third-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.
Stryker (SYK) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of -3.51% and -1.91%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Stocks to Watch as Demand for Surgical Robots Ready to Rise
by Kaustav Ghosh
Watch out for the likes of Asensus Surgical (ASXC), Stryker (SYK), Medtronic (MDT) and Intuitive Surgical (ISRG) as demand for surgical robots is set to rise, owing to the conveniences they offer.
5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space
by Debanjana Dey
OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.
Stryker's (SYK) Trauma & Extremities Arm Unveils New Product
by Zacks Equity Research
The newly launched Citrelock Tendon Fixation Device System expands Stryker's (SYK) Foot & Ankle offerings.